Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.

Autor: García-Donas J; HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain. jgarciadonas@hmhospitales.com., de Velasco G; Hospital Universitario 12 de Octubre, Madrid, Spain., Madurga R; Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain., Chamorro J; Hospital Universitario Ramón y Cajal, Madrid, Spain., Rosero D; Hospital Universitario Ramón y Cajal, Madrid, Spain., Etxaniz O; Hospital Germá Trials I Pujol, Barcelona, Spain., Pérez-Gracia JL; Clínica Universidad de Navarra, Pamplona, Spain., Pinto Á; Hospital Universitario La Paz, Madrid, Spain., Cacho D; Hospital Universitario Marqués de Valdecilla, Santander, Spain., Barba M; HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain., Borrega P; Hospital Universitario de Cáceres, Cáceres, Spain., Lázaro M; Hospital Álvaro Cunqueiro, Vigo, Spain., Rodriguez L; Hospital Universitario de Fuenlabrada, Madrid, Spain., Villalobos L; Hospital Universitario Príncipe de Asturias, Madrid, Spain., García L; Hospital de Segovia, Segovia, Spain., Cuellar A; Institut Català d'Oncologia, Badalona, Spain., Solís-Hernández MP; Hospital Universitario Central de Asturias, Oviedo, Spain., González A; Hospital Virgen de la Salud, Toledo, Spain., Pernaut C; Hospital Severo Ochoa, Madrid, Spain., Rodríguez-Moreno JF; HM Hospitales-Centro Integral Oncológico Clara Campal, Madrid, Spain.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Mar; Vol. 26 (3), pp. 732-738. Date of Electronic Publication: 2023 Aug 09.
DOI: 10.1007/s12094-023-03295-2
Abstrakt: Background: Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by standard treatments in kidney cancer (i.e., antiangiogenics or immunotherapy). Thus, understanding the impact of COVID19 in patients with this tumor is key for their correct management.
Methods: We designed a retrospective case-control study comparing the outcome of three groups of advanced kidney cancer patients on systemic treatment: cohort A (developed COVID19 while on antiangiogenics), cohort B (developed COVID19 while on immunotherapy) and cohort C (non-infected). Matching factors were age, gender, and treatment.
Results: 95 patients were recruited in 16 centers in Spain from September 2020 to May 2021. Finally, 85 were deemed as eligible (23 cohort A, 21 cohort B, 41 cohort C). Patients with COVID required more dose interruptions (25 vs. six) and hospitalizations (10 vs. none) than those without COVID (both p = 0.001). No difference between cohorts A and B was observed regarding hospitalization or length of stay. No ICU admission was registered and one patient in cohort B died due to COVID19. Regarding cancer evolution, three patients in cohort A presented progressive disease after COVID19 compared to two in cohort B. One case in cohort B, initially deemed as stable disease, achieved a partial response after COVID19.
Conclusions: Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy.
(© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
Databáze: MEDLINE
Externí odkaz: